CSL (OTCMKTS:CSLLY) Hits New 12-Month Low – Should You Sell?

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY) hit a new 52-week low on Thursday . The company traded as low as $24.49 and last traded at $24.81, with a volume of 403575 shares. The stock had previously closed at $25.32.

Analyst Ratings Changes

Several analysts have recently commented on CSLLY shares. Royal Bank Of Canada downgraded shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

CSL Price Performance

The firm’s 50-day moving average is $53.01 and its 200-day moving average is $59.83. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.